news roundup
WCG has acquired biopharma consultancy Waife & Associates (W&A). W&A will continue to provide analysis, implementations and recommendations to address a range of organizational and technology questions around the clinical development process. W&A's Founder Ronald S. Waife becomes WCG's Chief Management Consulting Officer.
The Tufts Center for the Study of Drug Development, in collaboration with The Avoca Group, released its results from the first industrywide benchmarks of the vendor qualification process. Highlights include: vendor requalification cycle times are two to four weeks faster, on average, than new vendor qualifications and despite longer total assessment cycle times, large drug companies have the highest rates of vendors failing to qualify (11.5%), likely due to deeper inquiry into vendor practices.
|
|
advertisement
Anti-Microbial Resistance and the Role of Vaccines Europe: Thursday, November 14, 2019 at 3pm GMT | 4pm CET
North America: Thursday, November 21, 2019 at 11am EST | 10am CST | 8am PST
Register Now
|
|
Subscribe
 |
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »
|
|
|
|
Signant Health, formerly CRF Health and Bracket, has integrated its eCOA platform TrialMax with ActiGraph’s CentrePoint system. The integration, which includes ActiGraph’s FDA 510(k) cleared sensors, hopes to simplify the process of collecting and monitoring real-world activity, mobility, and sleep outcomes data for patients and researchers.
advertisement
Trends and Insights for Your Oncology Trial
Tuesday, November 12, 2019 at 10am EST
Register Now
|
Articles
This article examines imaging systems and services since its use is commonly used as a biomarker for safety in oncology development and in many trials is the primary efficacy endpoint.
The understanding of FSP, how it is evolving and how to get the best results from the model still are a puzzle to many, say the authors. For the purposes of this article, we define FSP as an outsourcing strategy where vendors provide a single service (statistics, pharmacovigilance or clinical monitoring, etc.) or a limited number of highly related services (site contracting, site payments, etc.).
advertisement
Launching Medical Devices in the Japanese Market
How to navigate regulatory and reimbursement approval
On Demand
|
|
|
|
advertisement
Will Decentralized Clinical Trials Compound Patient and Data Quality Risks?
On Demand
|
Blog Posts
Editorial Director Lisa Henderson writes that while industry has touted the statistic on the internal rate of return (IRR) on pharma R&D is predicted to be at 0% in 2020, there are some uplifiting developments around innovation that could erase this bleak prospect.
| |
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription
|
|
|
|
|
|